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Abstract
Background: Megakaryocytic cell maturation involves polyploidization, and megakaryocyte (MK) ploidy correlates
with their maturation and platelet production. Retardation of MK maturation is closely associated with poor MK
engraftment after cord blood transplantation and neonatal thrombocytopenia. Despite the high prevalence of
thrombocytopenia in a range of setting that affect infants to adults, there are still very limited modalities of
treatment.
Methods: Human CD34+ cells were isolated from cord blood or bone marrow samples acquired from consenting
patients. Cells were cultured and induced using 616452 and compared to current drugs on the market such as
rominplostim or TPO. Ploidy analysis was completed using propidium iodide staining and flow cytometry analysis.
Animal studies consisted of transplanting human CD34+ cells into NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice followed by
daily injections of 15 mg/kg of 616452.
Results: Within one week of culture, the chemical was able to induce polyploidization, the process required for
megakaryocyte maturation with the accumulation of DNA content, to 64 N or greater to achieve a relative adult
size. We observed fold increases as high as 200-fold in cells of 16 N or greater compared to un-induced cells with a
dose-dependent manner. In addition, MK differentiated in the presence of 616452 demonstrated a more robust
capacity of MK differentiation than that of MKs cultured with rominplostim used for adult idiopathic
thrombocytopenic purpura (ITP) patients. In mice transplanted with human cord blood, 616452 strikingly enhanced
MK reconstitution in the marrow and human peripheral platelet production. The molecular therapeutic actions for
this chemical may be through TPO-independent pathways.
Conclusion: Our studies may have an important impact on our fundamental understanding of fetal MK biology,
the clinical management of thrombocytopenic neonates and leukemic differentiation therapy.
Background
Megakaryocytes are one of few cell types that undergo
endomitosis, a form of cell cycle that skips the late stages of
mitosis to become polyploid [1–4]. Human megakaryocytes
commonly reach ploidy states of 16 N and can achieve states
as high as 128 N. The mechanism of polyploidization is still
not well understood, however, polyploidy is required for
functional human megakaryocyte maturation. Once active,
the megakaryocytes are responsible for the production of
platelets that have well-characterized roles in hemostasis,
thrombosis, vascular integrity, development of the lymphatic
system, and the innate immune response [5–8].
Thrombocytopenia affects approximately 20–35% of in-
fants admitted to the neonatal intensive care unit [9–11].
Approximately 9% of those infants are severe and experi-
ence clinically significant bleeding (usually intracranial).
Platelet transfusions are one of the only therapeutic
options for thrombocytopenic neonates. Recent studies
have shown that megakaryocytes of neonates are smaller
and have lower ploidy than those of adults [12, 13]. Small
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megakaryocytes usually produce fewer platelets than large
megakaryocytes and typically achieve adult size at
approximately 1 year of age. Therefore, an inability to
increase megakaryocyte size and ploidy in response to
increased platelet consumption might underlie the predis-
position of sick neonates to thrombocytopenia.
In adults, clinically significant thrombocytopenia is often
multifactorial often involving cytotoxic or suppressive
effects of chemotherapeutic agents and malignant cells,
respectively. Thrombopoietin (TPO) is synthesized in the
liver and is the primary regulator of megakaryocyte devel-
opment and maturation [14, 15]. Recombinant human
TPO (rhTPO) has been shown to attenuate carboplatin-
induced thrombocytopenia, reducing the need for platelet
transfusions [16]. However, the clinical development of
rhTPO has since been halted due to the natural develop-
ment of anti-TPO antibodies in patients. Alternative
routes to target TPO receptors such as eltrombopag, a
non-peptide, small molecule, that have been shown to
stimulate megakaryopoiesis of CD34+ cells in patients
with multiple myeloma are in the pipelines [17, 18].
Human umbilical cord blood (hUCB) is an important
stem cell source for patients who lack other suitable donors.
However, slower platelet engraftment is a major drawback
of hUBC transplantation. Platelet engraftment takes an
average of approximately 50 days for hUBC recipients, ver-
sus 20 days for mobilized peripheral blood cells derived
from adult donors [12]. Identification of a megakaryocyte
maturation inducer or co-transfusion of large numbers of
ex vivo generated human megakaryocyte-committed cells
with high maturation potential, could provide an alternative
method to shorten period of thrombocytopenia [19]. TPO
and its derivatives have been used in the treatment of
thrombocytopenia in adult but not neonatal patients. How-
ever, studies in models using the non-human primate or ca-
nine demonstrated that standard post-transplant admiration
of TPO could not accelerate platelet reconstitution follow-
ing autologous bone marrow transplantation (AuBMT ) or
allogenic bone marrow transplantation (alloBMT), respect-
ively, in myeloablated hosts [20–23]. TPO stimulates the
megakaryocyte formation in vivo, but it does not shorten its
maturation time [22].
Although the cellular and molecular mechanisms under-
lying the differences of neonatal and adult MKs remain un-
clear, studies in congenital disorders have begun to
elucidate these mechanisms. A transient myeloproliferative
disorder with immature MK features (impaired maturation
of MKs) is seen exclusively in fetuses and neonates with
Down syndrome and GATA1 mutations indicating that
thrombopoietin (TPO)-independent pathways may play a
critical role in neonatal/fetal MK maturation [22, 24, 25].
In this manuscript, we introduce and characterize a
novel chemical that has not yet been implicated in
megakaryopoiesis. We found that this chemical molecule
selectively increased polyploidization and shortened
maturation of cord blood MKs. The size and ploidy of
cord blood/adult mobilized peripheral blood megakaryo-
cytes were also dramatically increased in response to this
chemical small molecule stimulation with a dose-
dependent fashion. The chemical also induced human
peripheral platelet production in mice transplanted with
human cord blood. The molecular action of this chem-
ical to stimulate the shortened MK maturation may be
through TPO-independent pathways.
Methods
Isolation of CD34+ cells from mobilized peripheral blood,
bone marrow, or umbilical cord blood
Cells were isolated with MACS CD34+ microbead kit
following manufacturer protocols. In the isolation of
cord blood, cells underwent a lysis phase for 15 min at
room temperature using BD PharmLyse prior to under-
going the MACS CD34+ isolation protocol. Percentage
of viable CD34+ obtained ranged from 90–98% in purity.
HSC culture
Standard culture of CB cells used StemSpan SFEM (Stem-
Cell Technologies) containing 10% FBS (Gibco), 100 units/
ml Pen Strep, 100 ng/ml SCF, TPO, and Flt-3 ligand
(Peprotech). For expansion of cells targeted for cell sorting,
we used the same media containing a different cytokine
cocktail of 100 ng/ml SCF, TPO, and 10 ng/ml IL-3.
Chemicals
616452 and 616454 were purchased from Calbiochem.
SB431542 was purchased from Tocris. All chemicals
were reconstituted according to manufacturers’ instruc-
tions. For animal studies, the 616452 was purchased in
bulk from BioVision.
Ploidy Analysis
Cells were centrifuged for 5 min at 200g at 4 °C. Pellet
was resuspended in 70% ethanol for overnight at 4 °C.
After which, the cells were washed with PBS and centri-
fuged for 5 min at 200g at 4 °C. The pellets were resus-
pended in PI staining buffer containing PBS with 1%
Triton X-100, 100 ul of 2 mg/ml PI, and 0.25 ug/ml of de-
oxyribonuclease (DNAse)-free ribonuclease (RNAse). The
following suspension was incubated at room temperature
for 30 min prior to analysis.
Flow cytometry analysis
Cells were centrifuged for 5 min at 200g at 4 °C. Cells
were resuspended with CD34, 38, and/or 41 conjugated
antibody for 30 min on ice. Cells were then washed with
2 ml of PBS and centrifuged for 5 min at 200g at 4 °C.
The final pellet was resuspended using 300 ul of 2% for-
malin. Analysis was run on the FACSCalibur.
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Flow–cell sorting
Cells were centrifuged for 5 min at 200g at 4 °C and re-
suspended with 25 ul of CD41-FITC antibody for
30 min on ice. Cells are then washed gently with PBS
and centrifuged for 5 min at 200g at 4 °C. Cells are then
suspended at a concentration of 106 cells/ml of PBS con-
taining 2% FBS. Cells are sorted via FACSAria.
Animal study: platelet recovery upon injection of
chemical
Twelve 10-week-old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (Jack-
son Laboratories) male mice were given sublethal irradi-
ation of 2.25 Gy. The following day, mice were given 50000
CD34+ cells and 300000 progenitor cells (CD34+ cells that
were cultured for 4 days) via IV injection. Mice were given
daily 616452 injections at 15 mg/kg. Mice were bled via
submandibular bleeding every 3–4 days, and the collected
blood was analyzed using the HemaVet 950 for platelet and
cellular composition. The mice were sacrificed on day 12,
and their bone marrow was analyzed for CD34 and CD41.
Gene expression profile
Cells were induced using 616452 for 2 and 4 days with
the control cells induced with dimethyl sulfoxide
(DMSO). Cells were pelleted and flash frozen in liquid
nitrogen and analyzed using PAHS-054Z Hematopoiesis
array via Qiagen’s service center.
RNA isolation and quantitative real-time polymerase
chain reaction
Total RNA was isolated from human umbilical cord blood
cells treated with or without 616452 using the AllPrep
DNA/RNA Mini Kit (Qiagen Group). According to the
manufacturer’s protocol, 1 ug total RNA from each sample
was subjected to complementary DNA (cDNA) synthesis
using QuantiTect® Reverse Transcription Kit (Qiagen
Group). PCR was carried out using Power SYBRR Green
PCR Master Mix (Applied Biosystems) and performed on
a 7500-real-time PCR system (Applied Biosystems). The
data were analyzed using the delta-delta Ct method.
Results
Identification of small molecules that induce
polyploidization
Previously, we have shown that the stem cell gene SALL4
is a robust stimulator of expansion of hematopoietic
stem/progenitor cells [26–28] and plays a critical role in
hematopoietic differentiation. We screened small mole-
cules targeting SALL4 expression using a SALL4 luciferase
reporter. One TGF-β pathway inhibitor, 616452, was
identified as a strong inducer of SALL4 expression. When
cultured with isolated CD34+ cells, we noticed the appear-
ance of large megakaryocyte-like cells.
Induction of megakaryocyte differentiation and
maturation in bone marrow (BM) CD34+
Initially, 616452 was identified as a MK inducer in BM
CD34+ cells when a significant number of large mega-
karyocytes appeared within 4 days of culture. The con-
trol, induced with the compound solvent, only appeared
to have one or two cells. By 10 days of culture, the large
cells had taken over the dish (Fig. 1a–c). Live cell stain-
ing and immunofluorescence revealed all the large cells
were positive for CD41, a unique marker of megakaryo-
cytes [29] (Fig. 1d). Analysis by flow cytometry showed
an increase of two-fold in the CD41+ CD34+ population
within 4 days of culture (Fig. 1e). Giemsa-Wright stain-
ing revealed these cells are as large as 90 um with the
average around 50 um (Fig. 1f ). Although a dozen other
TGF-β inhibitors have been described, 616452 was the
only one we tested that strongly induced SALL4 stem
cell gene expression and stimulated MK progenitor cell
expansion and differentiation.
Potent agonist of cord blood (CB) megakaryocyte
differentiation and maturation from umbilical cord blood
Accumulated evidence demonstrates that neonatal MKs
are significantly smaller, of lower ploidy, and produce
fewer platelets than MKs from adults. Based on these
characteristics, MKs from fetuses and neonates have
been considered to be immature compared with adult
MKs. We then tested the chemical effects on neonatal
MK maturation. Cells isolated from human umbilical CB
were cultured in hematopoietic stem cell (HSC) media
induced with 616452 and compared DMSO-treated con-
trol cells. Larger cells characteristic of developing mega-
karyocytes appeared after 4 days of culture (Additional
file 1: Figure S1a). The quantity and size of cells in-
creased over time. By 8 days, the culture dishes were
predominately composed of megakaryocytes with the
formation of megakaryocytic clusters beginning. A
Giemsa-Wright stain of these cells revealed a lobular
multi-nucleated structure and a granulocytic cytoplasm
characteristic of megakaryocytes (Additional file 1: Fig-
ure S1c). Flow analysis revealed an increase of 44.8% of
the CD41+ population as well as an increase in the
CD34+ CD41+ population (Additional file 1: Figure S1b)
similar to that of bone marrow.
One of the unique characteristics of megakaryocytes is
their ploidy development, which can be easily measured
using propidium iodide (PI), a fluorescent intercalating
agent that binds nucleic acids. Cells induced with 616452
for 8 days revealed a drastically increased number of cells
with greater ploidy. In humans, megakaryocytes normally
account for approximately 0.05 to 0.1% of all nucleated
bone marrow cells. Out of 10000 events, the control cells
only elicited only 1 cell with a ploidy of 16 N and nothing
greater (Fig. 2a). The chemically induced cells produced
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over 100 cells of 16 N ploidy and registered ploidy num-
bers as high as 64 N. 616452 consistently induced greater
number of cells in each ploidy category 4 N and above.
These studies were repeated by multiple independent ex-
periments (n = 5).
616452 works independently of TPO
TPO has been highly associated with megakaryopoiesis,
and one concern was whether this inhibitor is working in
conjunction or is reliant on the presence of TPO. In the
absence of TPO, there was limited cell growth, but MK
development was still present with ploidy increase of 5–8-
fold over the control in cells of 8 N or greater ploidy
(Additional file 2: Figure S2g). In the presence of TPO,
cells of 8 N ploidy increased dramatically more with a 55-
fold increase over control. This likely suggests that 616452
is capable of functioning in a TPO-independent manner.
However, it also has large synergistic interactions with
TPO in accelerating the maturation of MKs.
Time and dose dependence
Chemical induction of CB CD34+ revealed that the longer
the cells were induced, the greater the ploidy develop-
ment. Between 8 and 12 days of induction, the number of
8 N, 16 N, and 32 N cells nearly doubled (Fig. 2a, b), while
the control remains almost unchanged. At 10 uM,
chemical induces ploidy in CB CD34+ cells compared with
control cells treated with TPO. Multiple replicates with
CB from different individuals (n > 3) indicated that there
is little or no 16 N ploidy in control cells. Cells treated
with varying concentrations of chemical indicated dose
dependence: 2.5 uM increased the numbers of 8 N ploidy
cells by 10-fold compared to control, whereas 40 uM in-
creased ploidy by 87-fold over the same population
(Fig. 2c). There is also a time-dependent response with an
increase in ploidy for up to 6 days in culture (Fig. 2d).
MK differentiated in the presence of 616452
demonstrated a much robust capacity of MK
differentiation than that of MKs cultured with
Rominplostin (Amgen)
We observed a significant difference between the cells in-
duced with 616452 compared to a current drug, romiplos-
tim used for adult ITP patients. CB CD34+ co-cultured
with 616452 showed numerous large MK cells within 8 days
of culture as compared to that of rominplostim, which had
little to none (Fig. 3a). The cells induced with romiplostim
showed no significant difference from the control while
Fig. 1 616452 induces megakaryopoiesis in human BM CD34+ cells. A representative plot of the effectiveness of the chemical 616452, and how
the induction of megakaryopoiesis was induced (a). BM CD34+ cells were induced with 616452 (10 uM) for 8 days and compared to control
(b, c). The induced cells were stained by live cell staining for CD41 (d) and analyzed by flow cytometry on day 5 (e). Cells were also collected for
Giemsa-Wright staining after 10 days of culture (f), to illustrate the multi-nucleated and lobular nature of the nuclei
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cells induced with 616452 had an 8- and 30-fold increase in
cells of 8 N and 16 N ploidy, respectively (Fig. 3b). The
greater ploidy cells (32 N) could be seen both visually and
phenotypically in the induced 616452 cultures which
appeared drastically different than that of the control and
romiplostim.
The extent of CD41+ megakaryocytic population in
response to the induction of 616452
CB CD34+ cells were initially cultured for 8 days in a
media specific to megakaryocyte expansion [30]. The cells
were labeled with a conjugated CD41 antibody and sorted
by FACS (Fig. 4a). The resulting CD41+ cells were induced
with the small chemical, and cells began to increase their
size within 2 days. By day 6, approximately 80% of the
cells appeared to be large in size by eye while the control
had little to none (Fig. 4e, f). Aggregation of the cells
began around day 4 with clusters of about 5–15 cells, 25–
50 cells by day 6 and by day 8 the majority of cells were in
clusters of hundreds of cells. The control meanwhile had
little clusters, but none that compared in size and num-
bers as the induced cells (Fig. 4g–j). A live cell stain re-
vealed that 95% of the cells that were present after 8 days
of induction with the small chemical were positive. The
live cell stain also gave some insight into the structure of
the large cell clusters as mainly comprised of large MKs
(Fig. 4k, l). Out of 10000 events, a ploidy analysis of the
cells after 8 days of induction revealed 2018 cells of 8 N,
585 cells of 16 N, and 86 cells of 32 N or greater ploidy
(Fig. 4b, c). Approximately 54% of the cells had a ploidy
number of 4 N or greater while the control cells induced
with only TPO had only 6% of the cells with a ploidy of
4 N or greater (Fig. 4d). There were 69 cells with 8 N
ploidy and nothing greater in the control cells. Meanwhile,
in our small chemical induced cells, CD41-cells were also
cultured under the same conditions with the control being
induced using TPO and DMSO. There was little to no
ploidy development in the control.
Synergistic effect of combined TGF-β inhibition
Two additional TGF-β pathway inhibitors, 616454, and
SB431542 (Fig. 5a), were tested for their ability to induce the
expression of CD41 and/or the maturation of megakaryo-
cytes via ploidy analysis. In both these cases, there were no
observed increases in CD41 expression within 4 days, and
no visible differences in cell size compared to control within
10 days of culture. A ploidy analysis revealed no significant
deviation from the control with these two chemicals (Fig. 5b).
However, when all these inhibitors were combined with
616452, we noticed a synergistic effect of chemicals on the
Fig. 2 Dose and time dependence of 616452. Ploidy analysis of the MK’s derived from CB CD34+ cells after 8 and 12 days of culture (a, b). Cells
were induced with 616452 (10 uM), and analysis were done on the respective days using PI staining and flow cytometry (n > 5). Dose-dependent
analysis (n = 3) was done on CB CD34+ cells (c) with 1× concentration as 10 uM. Time-dependence studies (n = 3) used CB CD41+ cells that were
isolated by flow cytometry (d). Cells were cultured for 6 days and chemicals were removed at certain time points and replaced with media
containing only TPO. The control cells were grown entirely with TPO
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expression of CD41 to a nearly 2-fold increase over the con-
trol (Fig. 5b, c) increasing the CD41 expression from 10.02
to 20.26%. Ploidy was also significantly affected with a 50
and 93% increase in cells of 8 and 16 N ploidy, respectively.
Gene expression profile
Real-time PCR (RT-PCR) examined the expression of a
focused panel of 81 genes (Table 1) related to
hematopoietic cells (Qiagen’s PAHS-054Z hematopoiesis
array) in vehicle and chemical-treated CD34+ cells from
human cord blood. Since maturation does not visually
occur until day 4 of induction, cells induced for 2 and
4 days were compared to un-induced controls (Fig. 6a).
There was a significant difference between 2 and 4 day-
induced cells with about 15 genes upregulated and 1
downregulated on day 2, and 38 genes upregulated and
4 genes downregulated on day 4. Most noticeably, the
genes associated with megakaryopoiesis that is related to
TPO-independent pathways (Notch1 or 2, GATA1,
GATA2, iL1, iL6, iL10, and SCF) were up regulated.
Repeat RT-PCR study further confirmed the significant
fold increases in CD14, CD80, CSF1, GATA1, GATA2,
IL10, JAG1, JAG2, NOTCH2, and PF4 which may give
clues to the mechanism of action mainly related with
TPO-independent pathways (Fig. 6b).
616452 induces human platelet production in NSG mice
Several animal models were tested, but the main model
used looked at the ability of CD34+ cells to differentiate
mature and secrete platelets (Fig. 7a). Twelve 10-week-old
NSG mice were given irradiation and subsequently
followed by CD34+ transplantation. The cells were allowed
to home into their niche for 3 days prior to the daily injec-
tions of 616452 chemical at 15 mg/kg via intraperitoneal
(IP) or intravenous (IV) injections. Injections lasted for
12 days. On day 8, the mice were analyzed for human
platelets using a tail bleed and were found to have signifi-
cant increases of at least 50% in human platelets com-
pared to that of control, induced with DMSO/PBS
solution (Fig. 7b). Analysis on day 12 of the mice’s
Fig. 3 616452 on selectively isolated CD41+ cells CB CD34+ cells were cultured with TPO, SCF, IL-3 for 7 days prior for CD41 selection by flow cy-
tometry (a). Control (DMSO induced) and chemical induced cells were grown(n=2) in StemSpan containing only TPO for 8 days prior to cell cycle
analysis (b). In control cells we observed only 6% of the cells increased their ploidy numbers with no cells reaching a ploidy of 16N or greater,
while 54% of the chemically induced cells had a nuclei of 4N or greater with a 4.5 fold increase in the number of 4N, 30 fold increase in 8N and
the appearance of cells with even greater ploidy reaching as high as 64N within 8 days of culture (c, d). CB CD41+ cells were isolated using flow
cytometry and cultured in the absence (e) or presence (f) of 616452(10uM). Cells appeared mostly as single cells on prior to day 6 (e, f) but began
to form clusters thereon, while the control had little to none (g). By 8 days of induction, the clusters were large and covered the entire plate (h, i,
j). A CD41 staining of these clusters illustrates the composition of these clusters as mainly large MK-like cells(k, l)
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peripheral blood and bone marrow revealed a slight in-
crease in MK engraftment via hCD41+ in the BM and little
to no difference in the platelet measurements. IP injec-
tions were found to have little to no effect compared to IV
likely due to first pass metabolism of the drug.
Statistical analysis
Results are presented as the mean +/−the standard devi-
ation. Statistical significance was confirmed using unpaired
student’s t test, Mann-Whitney test, or analysis of variance.
Discussion
There is a large difference between cells isolated from BM
and those from CB. In vitro culture of BM CD34+ cells re-
sults in small percentage (<1%) of cells becoming large
megakaryocytes by morphology. However for cord blood,
there is a significant delay with no large cells appearing at
all in the first 12 days of culture. This delay is of signifi-
cant importance as it introduces many platelet-derived is-
sues during CB transplantations, which are frequently
associated with a late recovery and engraftment of periph-
eral blood cells of donor origin as compared to
transplantation of BM or mobilized PB. As a result, pa-
tients present with thrombocytopenia and delayed hospital
stays due to insufficient platelet counts. To date, the major
proponent used in the development and maturation of
megakaryocytes is thrombopoietin (TPO) which was used
in all our experiments as the control.
We initially discovered 616452 when CD34+ cells in-
duced with it produced a significant number of large
megakaryocyte-like cells. Within four days of induction,
there was an abundance of megakaryocytes, and they only
continued to increase in size. These large cells were 2–16
times the size of the typical cells in the control. In fact, the
control cells when induced with only TPO had little to no
observable increase in cell sizes. Cell cultures typically
lasted only eight days after induction due to aggregation
and formation of MK-burst forming colonies (Fig. 4i–l).
Analysis of cells after day 8 resulted in inconsistent results
due to the nature of colonies as well as ease in which the
MKs could be lysed by simple pipetting techniques.
These large cells were identified by their morphology,
phenotype, and functionality. A Giemsa-Wright stain
displayed typical megakaryocyte morphology of lobular
Fig. 4 616452 on selectively isolated CD41+ cells. CB CD34+ cells were cultured with TPO, SCF, and IL-3 for 7 days prior for CD41 selection by flow
cytometry (a). Control- (DMSO induced) and chemical-induced cells were grown (n = 2) in StemSpan containing only TPO for 8 days prior to cell
cycle analysis (b). In control cells, we observed only 6% of the cells increased their ploidy numbers with no cell reaching a ploidy of 16 N or
greater, while 54% of the chemically induced cells had a nuclei of 4 N or greater with a 4.5-fold increase in the number of 4 N, 30-fold increase
in 8 N, and the appearance of cells with even greater ploidy reaching as high as 64 N within 8 days of culture (c, d). CB CD41+ cells were isolated
using flow cytometry and cultured in the absence (e) or presence (f) of 616452(10 uM). Cells appeared mostly as single cell on prior to day 6
(e, f) but began to form clusters thereon, while the control had little to none (g). By 8 days of induction, the clusters were large (h) and covered
the entire plate (i, j). A CD41 staining of these clusters illustrates the composition of these clusters as mainly large MK-like cells (k, l)
Huang et al. Journal of Hematology & Oncology  (2016) 9:136 Page 7 of 11
Fig. 5 Comparison of 616452 against other TGF-β inhibitors. Various other TGF-β (a) were tested against 616452. Flow cytometry of CB CD34+
after 4 day induction (b) revealed inhibitors 616454 and SB431542 had little to no effect and may even negatively impact the differentiation into
CD41+ cells while 616452 enriches the development by ~25%. The three TGF-b inhibitors induced at the following concentrations: 616454 (4) –
10uM, SB431542(5) - 10uM, 616452(6) – 10uM. When all three inhibitors combined, there is nearly a 100% increase in the enrichment. A ploidy
analysis of the cells was run after 4 of induction the chemicals (c) to reveal an improved rate of maturation in terms of ploidy development on
both days
Table 1 Genes studied under the effect of 616452
ANGPT1 CD2 CD8A FLT3LG IL10 INHA LRMP PAX5 STAT1 VAV1
APC CD27 CEBPE FUT10 IL11 INHBA MAL PECAM1 STAT3 VEGFA
ASH2L CD34 CEBPG FZD1 IL12B JAG1 MAP4K1 PF4 STIM2 WNT3A
BLNK CD3D CHST15 GATA1 IL1A JAG2 MMP9 PTPRC TAL1 ACTB
CBFB CD3G CSF1 GATA2 IL2 KDR NCOA6 RBPJ TEK B2M
CCR1 CD4 CSF2 HDAC4 IL20 KIT NOS2 RUNX1 TLR3 GAPDH
CD14 CD44 DLL1 HDAC5 IL25 KITLG NOTCH1 SFXN1 TLR4 HPRT1
CD164 CD80 ETS1 HDAC7 IL31RA LEF1 NOTCH2 SOCS5 TNFSF11 RPLP0
CD1D CD86 ETV6 HDAC9 IL6ST LMO2 NOTCH4 SPP1 TRIM10 HGDC
Table of the 81 genes analyzed under 2 and 4 days of induction
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Fig. 6 Gene expression profile and RT-PCR of cells after 4 days of induction. Gene expression profile of CB CD34+ cells induced for 2 and 4 days
compared to control (a). There are noticeably more genes expressed and at higher levels on 4 days of induction compared to that of day 2. There
are 18 genes total upregulated on day 2, and by day 4, there were 38. On the right is a heat map illustrating the values of expression in terms of
fold increase over control. Green is indicative of upregulation while red is downregulation. Quantification of the expression level of related genes
in human umbilical cord blood cells treated with or without 616452 harvested at day 4 by quantitative PCR (b). 616452 untreated umbilical cord
blood cells were used as controls as shown in the figure. The values were normalized by GAPDH expressed as relative quantitation (RQ), the error
bars depict the SD (n = 3)
Fig. 7 616452 effect in mice. Twelve 10-week old mice were sublethally irradiated and transplanted with human CB CD34+ and then given either
control injections or iMK injections at 15mg/kg (a). Platelet analysis was done on day 8 (b) and was found to have significantly increased platelet
counts compared to control
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and multi-nucleated nucleus with a granular cytoplasm.
Analysis by flow and live cell staining revealed these large
cells to be CD41 positive, a protein typically expressed on
platelets and megakaryocytes. Additionally, the induced
cells were found to have drastically increased nuclear DNA
content compared to control with cells developing ploidy
numbers as great as 64 N within 8 days of induction.
Between experiments (>5), there was an inconsistency
in the number of large cells among the samples from
different patients. While the CD41 population appeared
to increase regardless of the patient, the population
seemed to differ drastically between certain patients.
This was likely caused by the variation of megakaryocyte
precursors among patients. Using flow cytometry, we
sorted the cells for CD41+ and CD41− cells. Both popu-
lations were then induced using the small chemical and
TPO. We found that the CD41+ population induced
with the chemical had increased ploidy of 4 N or greater
in over 50% of the cells while the control cells only had
approximately 6%, an increase of nearly 10-fold. In the
CD41− population, there was only an increase in 3% of
cells of 4 N or greater ploidy compared to non-induced.
While not perfect, a small fraction of CD41+ cells or
hematopoietic stem cell remained after sorting that de-
veloped into the MK lineage explains the slight increase
in the number of ploidy cells.
Often associated with megakaryopoiesis, one concern
was the dependence of this chemical on the presence of or
priming by, in the case of CD41+ cells, TPO. CB CD34+
cells were induced with the chemical for 8 days in the pres-
ence and absence of TPO, and it was found that the in-
crease of MK maturation increased in nearly all conditions,
with or without TPO (Additional file 2: Figure S2g). How-
ever, the presence of cytokines does increase overall cell
counts and copy number of MK genes, which produces lar-
ger numbers of MKs.
The hematopoietic stem cells (HSCs) of various other
species such as monkey and mouse were isolated and in-
duced with the same chemical. A comparison against hu-
man HSCs revealed the chemical to be the most potent in
monkey with a 30–200% increase in ploidy development of
certain sizes and nearly 2000%-fold greater than that of
mouse HSCs (Additional file 3: Figure S3). Even so, each
species still experienced an increase in ploidy development.
The efficacy of this small molecule on platelet produc-
tion was initially tested in various mouse models to no
avail. It was found that the delivery of this chemical was
of great importance. When given via intraperitoneal (IP)
injections, the mice experienced no effect and in fact
had a negative impact on the mice. The optimal mode of
delivery was via intravenous (IV) injections. Many mice
models failed initially, but after the discovery that mice
HSCs are significantly less impacted by the chemical
than that of human or monkey HSCs, a new transplant
model was developed. The mice were given a sublethal
dose of irradiation at 2.25 Gy to make room for engraft-
ment and then injected with 50000 CD34+ cells and
300000 progenitor cells (CD34+ cells cultured for 4 days).
The mice were then given 3 days of rest to allow the
cells to hone into their respective niches after which
each mouse was administered one daily dose of the
chemical at 15 mg/kg. On day 8, we found that human
platelet production in the induced mice were 50%
greater than the control mice.
The concentration of 616452 used varied from 2.5–
40 uM. Although there appeared to be potent effects at
higher concentrations, they could be difficult to achieve in
vivo. The side effect profile could be of great concern as
mice injected with 50 mg/kg showed significant toxicity
(data not shown) with the majority of the mice dying be-
fore the conclusion of the in vivo assay. This side effect
profile is of great concern when thinking about the trans-
lational effect to clinical medicine, and therefore further
studies on the toxicities and delivery mechanisms by
which to reduce such toxicities are necessary.
Conclusion
616452 is a TGF-β inhibitor that provides a novel pathway
for the induction of megakaryocytes that do not work like
the SRC kinase inhibitors like diMF or SU6656 or any Aur-
ora A Kinase inhibitors. Unlike other compounds, 616452
does not have much in vitro toxicity at the concentrations
tested in this manuscript and is able to enhance the differ-
entiation into megakaryocytes and speed their maturation.
This small chemical provides a new approach toward
megakaryocytic diseases that has the potential for clinical
treatments without unwanted side effects of other inhibi-
tors caused by their toxicity to all cells.
Additional files
Additional file 1: Figure S1. 616452 induces megakaryopoiesis in human
cord blood (CB) CD34+ cells. Chemical induction of CB CD34+ using 616452
(10 uM) for 8 days compared to control (a). Cells were analyzed by flow
cytometry for CD41 on day 5 (b) and also stained using a Giemsa-Wright Stain
after 8 days culture to illustrate the granular cytoplasm, and the multi-
nucleated and lobular nature of the nuclei (c). (JPG 146 kb)
Additional file 2: Figure S2. 616452 and TPO independence and
synergy. BM and CB CD34+ cells were cultured in the presence of SCF and
TPO. In 4 days of culture, the cells were all healthy and relatively the same
size (a,b). By 8 days of culture, BM cells appeared to have a few (<1%)
megakaryocytes with a size approximately four times that of a regular HSC
(c). CB however, had no such cells (d). Those cells induced with 616452 for
both BM and CB developed a significant number of large MKs (e,f). When
CB CD34+ cells were induced with 616452 for 8 days under various cytokine
conditions (g), it was found that 616452 works independently of either SCF
or TPO inducing MK maturation under all conditions. (JPG 193 kb)
Additional file 3: Figure S3. 616452 on monkey BM CD34+ cells.
Monkey CD34+ cells were purchased from Lonza and mouse HSCs were
isolated using ckit + MACs isolation kit. Human CD34+ were isolated from
cord blood. Cells were cultured for 6 days with 616452 or DMSO for
6 days prior to analysis via propidium iodide staining. (JPG 37 kb)
Huang et al. Journal of Hematology & Oncology  (2016) 9:136 Page 10 of 11
Acknowledgements
The authors would like to thank Kevin Pinz for his technical help.
Funding
This study was supported by a grant from NYSTEM.
Availability of data and materials
All relevant data and materials within this work are made available in this
manuscript. Any additional information can be made freely available to any
scientist on reasonable request.
Authors’ contributions
NH and YM conceived and designed the studies. YM supported financially.
CA worked with patients and collected the major of samples used in these
studies. ML and HA contributed to the collection and assembly of data. NH,
YM, HA, and ML interpreted the data. All authors read and approved the
final manuscript.
Competing interests
YM is a founder of iCell Gene Therapeutics LLC and Marrowsource




Ethics approval and consent to participate
The manuscript involved the use of human and animal samples. All animal
procedures and handling of samples are compliant with our institutional
IACUC protocol [278623-33] SALL4 in Hematopoiesis and Leukemogenesis,
IACUC #: 2001-1771-FAR-11.16.18- MI. All human samples were obtained with
informed consent and compliant with IRB protocol: [179617-8] Stem Cells in
Hematopoiesis. The assurance number is FWA 00000125.
Author details
1Department of Pathology, State University of New York, Stony Brook
Medicine, Stony Brook, NY 11794, USA. 2Department of Obstetrics &
Gynecology, State University of New York, Stony Brook Medicine, Stony
Brook, NY, USA.
Received: 6 September 2016 Accepted: 11 November 2016
References
1. Jackson CW. Megakaryocyte endomitosis: a review. Int J Cell Cloning. 1990;
8(4):224–6.
2. Lordier L, Jalil A, Aurade F, Larbret F, Larghero J, Debili N, Vainchenker W,
Chang Y. Megakaryocyte endomitosis is a failure of late cytokinesis related
to defects in the contractile ring and Rho/Rock signaling. Blood. 2008;
112(8):3164–74.
3. Lordier L, Pan J, Naim V, Jalil A, Badirou I, Rameau P, Larghero J, Debili N,
Rosselli F, Vainchenker W, Chang Y. Presence of a defect in karyokinesis
during megakaryocyte endomitosis. Cell Cycle. 2012;11(23):4385–9.
4. Arriaga M, South K, Cohen JL, Mazur EM. Interrelationship between mitosis
and endomitosis in cultures of human megakaryocyte progenitor cells.
Blood. 1987;69(2):486–92.
5. Bertozzi CC, Hess PR, Kahn ML. Platelets: covert regulators of lymphatic
development. Arterioscler Thromb Vasc Biol. 2010;30(12):2368–71.
6. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and
atherothrombosis. Int J Biochem Cell Biol. 2010;42(11):1762–6.
7. Ho-Tin-Noe B, Demers M, Wagner DD. How platelets safeguard vascular
integrity. J Thromb Haemost. 2011;9 Suppl 1:56–65.
8. Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum.
Nat Rev Immunol. 2011;11(4):264–74.
9. von Lindern JS, van den Bruele T, Lopriore E, Walther FJ. Thrombocytopenia
in neonates and the risk of intraventricular hemorrhage: a retrospective
cohort study. BMC Pediatr. 2011;11:16.
10. Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood
Rev. 2008;22(4):173–86.
11. Homans A. Thrombocytopenia in the neonate. Pediatr Clin N Am. 1996;
43(3):737–56.
12. Ignatz M, Sola-Visner M, Rimsza LM, Fuchs D, Shuster JJ, Li XM, Jotwani A, Staba S,
Wingard JR, Hu Z, Slayton WB. Umbilical cord blood produces small
megakaryocytes after transplantation. Biol Blood Marrow Transplant. 2007;13(2):
145–50.
13. Fuchs DA, McGinn SG, Cantu CL, Klein RR, Sola-Visner MC, Rimsza LM.
Developmental differences in megakaryocyte size in infants and children.
Am J Clin Pathol. 2012;138(1):140–5.
14. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal
B, Nichol JL, Swift S, et al. Identification and cloning of a megakaryocyte
growth and development factor that is a ligand for the cytokine receptor
Mpl. Cell. 1994;77(7):1117–24.
15. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ,
Heipel MD, Burkhead SK, Kramer JM, et al. Cloning and expression of
murine thrombopoietin cDNA and stimulation of platelet production in
vivo. Nature. 1994;369(6481):565–8.
16. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP,
Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ.
Recombinant human thrombopoietin attenuates carboplatin-induced
severe thrombocytopenia and the need for platelet transfusions in patients
with gynecologic cancer. Ann Intern Med. 2000;132(5):364–8.
17. Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ. The
non-peptide thrombopoietin receptor agonist eltrombopag stimulates
megakaryopoiesis in bone marrow cells from patients with relapsed
multiple myeloma. J Hematol Oncol. 2015;8:37.
18. Fujimi A, Kamihara Y, Hashimoto A, Kanisawa Y, Nakajima C, Hayasaka N,
Yamada S, Okuda T, Minami S, Ono K, Iyama S, Kato J. Identification of anti-
thrombopoietin receptor antibody in prolonged thrombocytopenia after
allogeneic hematopoietic stem cell transplantation treated successfully with
eltrombopag. Int J Hematol. 2015;102(4):471–6.
19. Fuentes R, Wang Y, Hirsch J, Wang C, Rauova L, Worthen GS, Kowalska MA,
Poncz M. Infusion of mature megakaryocytes into mice yields functional
platelets. J Clin Invest. 2010;120(11):3917–22.
20. Farese AM, MacVittie TJ, Roskos L, Stead RB. Hematopoietic recovery following
autologous bone marrow transplantation in a nonhuman primate: effect of
variation in treatment schedule with PEG-rHuMGDF. Stem Cells. 2003;21(1):79–89.
21. Neelis KJ, Dubbelman YD, Wognum AW, Thomas GR, Eaton DL, Egeland T,
Wagemaker G. Lack of efficacy of thrombopoietin and granulocyte colony-
stimulating factor after high dose total-body irradiation and autologous stem cell
or bone marrow transplantation in rhesus monkeys. Exp Hematol. 1997;25(10):
1094–103.
22. Zheng C, Yang R, Han Z, Zhou B, Liang L, Lu M. TPO-independent
megakaryocytopoiesis. Crit Rev Oncol Hematol. 2008;65(3):212–22.
23. Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B,
Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in
translational oncology: can we translate into clinical application? J Hematol
Oncol. 2015;8:16.
24. Queiroz LB, Lima BD, Mazzeu JF, Camargo R, Cordoba MS, Magalhães QI,
Martins-de-Sa C, Ferrari I. Analysis of GATA1 mutations and leukemogenesis
in newborns with Down syndrome. Genet Mol Res. 2013;12(4):4630–8.
25. Alford KA, Reinhardt K, Garnett C, Norton A, Bohmer K, von Neuhoff C,
Kolenova A, Marchi E, Klusmann JH, Roberts I, Hasle H, Reinhardt D, Vyas P,
International Myeloid Leukemia-Down Syndrome Study G. Analysis of
GATA1 mutations in Down syndrome transient myeloproliferative disorder
and myeloid leukemia. Blood. 2011;118(8):2222–38.
26. Aguila JR, Liao W, Yang J, Avila C, Hagag N, Senzel L, Ma Y. SALL4 is a
robust stimulator for the expansion of hematopoietic stem cells. Blood.
2011;118(3):576–85.
27. Aguila JR, Mynarcik DC, Ma Y. SALL4: finally an answer to the problem of
expansion of hematopoietic stem cells? Expert Rev Hematol. 2011;4(5):479–81.
28. Yang J, Aguila JR, Alipio Z, Lai R, Fink LM, Ma Y. Enhanced self-renewal of
hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4.
J Hematol Oncol. 2011;4:38.
29. Debili N, Louache F, Vainchenker W. Isolation and culture of megakaryocyte
precursors. Methods Mol Biol. 2004;272:293–308.
30. Nikougoftar Zarif M, Soleimani M, Abolghasemi H, Amirizade N, Abroun S,
Kaviani S. The high yield expansion and megakaryocytic differentiation of
human umbilical cord blood CD133(+) Cells. Cell J. 2011;13(3):173–8.
Huang et al. Journal of Hematology & Oncology  (2016) 9:136 Page 11 of 11
